GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Notes Receivable

TRML (Tourmaline Bio) Notes Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Notes Receivable?

Tourmaline Bio's Notes Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Tourmaline Bio Notes Receivable Historical Data

The historical data trend for Tourmaline Bio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Notes Receivable Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
- - -

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Tourmaline Bio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Tourmaline Bio Notes Receivable Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio Business Description

Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.